Conference allows Genomind to promote Assay for optimal treatment strategies for young patients.
CHALFONT, PA – October 21, 2014 – Genomind is pleased to announce its participation as an exhibitor for the second year at the American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting, being held at the Manchester Grand Hyatt and Marriott Marquis & Marina in San Diego, California, on October 20-25.
The AACAP Annual Meeting brings together the industry’s top health care professionals dedicated to helping pediatric psychiatric patients, a population Genomind is committed to serving. While the Genecept™ Assay is designed for and utilized by all ages, 25% of the patients who have been tested to date are children and adolescents. By helping clinicians better understand the underlying genetic disposition of their young patients, the Assay facilitates more appropriate treatment strategies and a much-improved quality of life.
“It’s difficult for children to verbalize how they are feeling, let alone how various medicines are impacting them,” said Dr. Jay Lombard, chief scientific officer and co-founder of Genomind. “Our hope is the Genecept Assay can save these children and their families the difficult process of trial and error, instead pointing us as quickly as possible to responsive treatments and allowing these young patients to return to simply being kids.”
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind